Pregabalin Solution
Product Images NDC 59762-1576

15 FDA label images from Mylan Pharmaceuticals Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 59762-1576). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Mylan Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Cockcroft And Gault Equation (Image 01)

Cockcroft And Gault Equation (Image 01)
An illustration showing the formula to calculate creatinine clearance (CLCr) based on age, weight, and serum creatinine, with a factor adjustment for female patients. The formula uses 140 minus age, multiplied by weight, divided by serum creatinine times 72, then multiplied by 0.85 for females.*
FDA Label Image

Pregabalin Structural Formula (Image 02)

Pregabalin Structural Formula (Image 02)
Chemical structure of pregabalin, showing its molecular arrangement with amino and carboxyl functional groups, consistent with the active ingredient in the product Pregabalin oral solution 20 mg/mL by Mylan Pharmaceuticals Inc.*
FDA Label Image

Figure 1: Patients Achieving Various Levels Of Improvement In Pain Intensity – Study Dpn 1 (Image 03)

Figure 1: Patients Achieving Various Levels Of Improvement In Pain Intensity – Study Dpn 1 (Image 03)
A line graph showing percent of patients improved versus percent improvement in pain from baseline. Four lines compare outcomes for Pregabalin 200 mg three times a day, 100 mg three times a day, 25 mg three times a day, and placebo, illustrating varying degrees of pain improvement across these groups.*
FDA Label Image

Figure 2: Patients Achieving Various Levels Of Improvement In Pain Intensity – Study Dpn 2 (Image 04)

Figure 2: Patients Achieving Various Levels Of Improvement In Pain Intensity – Study Dpn 2 (Image 04)
This is a line graph showing the percentage of patients improved versus percent improvement in pain from baseline. Two groups are compared: one receiving Pregabalin 100 mg three times a day and a placebo group. The graph shows a higher percentage of patients improved in the Pregabalin group across varying levels of pain improvement.*
FDA Label Image

Figure 3: Patients Achieving Various Levels Of Improvement In Pain Intensity – Study Phn 1 (Image 05)

Figure 3: Patients Achieving Various Levels Of Improvement In Pain Intensity – Study Phn 1 (Image 05)
A line graph depicting the percent of patients improved versus percent improvement in pain from baseline. The graph compares four groups: Pregabalin 300 mg twice a day, Pregabalin 150 mg twice a day, Pregabalin 75 mg twice a day, and Placebo, showing varying levels of pain improvement.*
FDA Label Image

Figure 4: Patients Achieving Various Levels Of Improvement In Pain Intensity – Study Phn 2 (Image 06)

Figure 4: Patients Achieving Various Levels Of Improvement In Pain Intensity – Study Phn 2 (Image 06)
A line chart showing the percent of patients improved plotted against percent improvement in pain from baseline for Pregabalin at two dosages (100 mg and 200 mg, taken three times a day) compared to placebo. The graph depicts comparative efficacy trends in pain improvement.*
FDA Label Image

Figure 5: Patients Achieving Various Levels Of Improvement In Pain Intensity – Study Phn 3 (Image 07)

Figure 5: Patients Achieving Various Levels Of Improvement In Pain Intensity – Study Phn 3 (Image 07)
A line graph showing percent improvement in pain from baseline on the x-axis and percent of patients improved on the y-axis. It compares three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo, illustrating the relationship between dosage and pain improvement.*
FDA Label Image

Figure 6: Responder Rate By Adjunctive Epilepsy Study (Image 08)

Figure 6: Responder Rate By Adjunctive Epilepsy Study (Image 08)
A bar chart comparing responder rates (%) between placebo and various doses of a drug in two studies (E1 and E3). Study E1 shows increasing responder rates with doses from 50 mg/day to 600 mg/day. Study E3 compares placebo, 600 mg/day immediate-release (IR), and 600 mg/day twice-daily (TID), showing higher responder rates for the active doses. Statistical significance versus placebo is indicated.*
FDA Label Image

Figure 7: Seizure Reduction By Dose (all Partial-onset Seizures) For Studies E1, E2, And E3 (Image 09)

Figure 7: Seizure Reduction By Dose (all Partial-onset Seizures) For Studies E1, E2, And E3 (Image 09)
A line graph showing the median percentage change from baseline in seizure reduction plotted against the dose in mg/day, comparing studies E1 BID, E2 TID, E3 BID, and E3 TID. The graph includes markers and significance levels (p-values) for doses ranging from 0 (placebo) to 600 mg/day.*
FDA Label Image

Figure 8: Responder Rate (greater Than Or Equal To 50% Reduction) (Image 10)

Figure 8: Responder Rate (greater Than Or Equal To 50% Reduction) (Image 10)
A bar chart showing responder rates (%) on the y-axis for three groups: Placebo, 2.5 mg/kg/day, and 10 mg/kg/day, with responder rates of 22.6%, 29.1%, and 40.6%, respectively. Sample sizes are indicated as 93, 103, and 96 for each group.*
FDA Label Image

Figure 9: Patients Achieving Various Levels Of Improvement In Pain Intensity – Fibromyalgia Study F1 (Image 11)

Figure 9: Patients Achieving Various Levels Of Improvement In Pain Intensity – Fibromyalgia Study F1 (Image 11)
A line graph depicting percent of patients improved versus percent improvement in pain from baseline for Pregabalin at doses of 600mg, 450mg, 300mg daily, and placebo. The X-axis represents the percent improvement in pain, while the Y-axis shows the percent of patients improved. Four distinct lines compare treatment doses to placebo over the range of improvement percentages.*
FDA Label Image

E 10: Time To Loss Of Therapeutic Response, Fibromyalgia Study F2 (kaplan-meier Analysis) (Image 12)

E 10: Time To Loss Of Therapeutic Response, Fibromyalgia Study F2 (kaplan-meier Analysis) (Image 12)
A line graph comparing the estimated percentage of subjects without LTR (likely loss to follow-up or a related measure) over 180 days between Pregabalin and Placebo groups. The graph shows a higher retention rate in the Pregabalin group compared to the Placebo group across the study period.*
FDA Label Image

Figure 11: Patients Achieving Various Levels Of Improvement In Pain Intensity – Study Sci 1 (Image 13)

Figure 11: Patients Achieving Various Levels Of Improvement In Pain Intensity – Study Sci 1 (Image 13)
A line graph comparing the percent of subjects improved from baseline to week 12 on the BOCF scale between Pregabalin and placebo groups. The x-axis represents the percent improved, ranging from 0 to 100, and the y-axis shows the percent of subjects improved. Pregabalin shows a higher percent of subjects improved compared to placebo across the range.*
FDA Label Image

Figure 12: Patients Achieving Various Levels Of Improvement In Pain Intensity – Study Sci 2 (Image 14)

Figure 12: Patients Achieving Various Levels Of Improvement In Pain Intensity – Study Sci 2 (Image 14)
A line graph depicting the percent of subjects improved over time from baseline to week 16 BOCF. The x-axis represents the percentage improved from 0 to 100, while the y-axis shows the percent of subjects improved from 0 to 100. Two lines are present: a solid line for Pregabalin and a dashed line for placebo, showing a higher percentage of subjects improved in the Pregabalin group compared to placebo across the improvement scale.*
FDA Label Image

Pregabalin Oral Solution 20 mg Per mL Carton Label (Image 22)

Pregabalin Oral Solution 20 mg Per mL Carton Label (Image 22)
Packaging label for Pregabalin oral solution 20 mg per mL by Greenstone, a Mylan Pharmaceuticals Inc. product. The label states 'for oral use only', includes the volume of 16 fl oz (473 mL), and indicates it is for prescription use only. Storage and dispensing instructions are also included, along with barcode and distributor details.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.